You are here:

mesalazine (Asacol)


Following an abbreviated submission

Mesalazine 800 mg modified release tablet (Asacol) is accepted for use in NHS Scotland for the maintenance of remission in ulcerative colitis and Crohn’s ileo-colitis.

At the recommended dose of up to 2.4g daily, the 800 mg strength allows halving of the pill burden compared with the 400 mg formulation at no extra cost.

Drug Details

Drug Name: mesalazine (Asacol)
SMC Drug ID: 224/05
Manufacturer: Procter and Gamble
Indication: Maintenance of remission in ulcerative colitis and Crohn's ileo-colitis
BNF Category:
Sub Category: 1.5 Chronic bowel disorders
Submission Type: Abbreviated Submission
Status: Accepted
Date Advice Published: 11 February 2008